Table 1

Characteristics of patients who received photodynamic therapy and intravitreal bevacizumab

Group A (photodynamic therapy)95% CIGroup B (intravitreal bevacizumab)95% CIp Value
No of patients1212NA
Age (year)62.4±7.562.3 to 62.662.8±8.062.7 to 63.00.896*
Refractive error (dioptre)−10.7±2.6−10.7 to −10.6−9.8±3.4−9.89 to −9.770.504*
Duration from onset (month)4.1±1.64.05 to 4.113.7±1.83.63 to 3.700.554*
Cases of predominantly classic CNV12121.000
Location of myopic choroidal neovascularisation1.000
 Juxtafoveal44
 Subfoveal88
Background fundus findings
 Posterior staphyloma11120.307
 Pupillary crescent12121.000
 Diffuse chorioretinal atrophy460.407
 Lacquer cracks230.615
Baseline
 Best-corrected visual acuity (logMAR)0.77±0.250.76 to 0.770.75±0.250.74 to 0.75>0.05
 CNV size (disc ratio)0.49±0.350.49 to 0.500.59±0.530.58 to 0.60>0.05
 Greatest linear dimension (μm)2781±12382758 to 28043294±17023262 to 33250.407*
 Foveal thickness (μm)299±94297 to 301267±47267 to 2680.310*
 CNV thickness (μm)494±82492 to 495473±105471 to 4750.584*
 Chorioretinal atrophy around CNV (disc ratio)0.47±0.60.46 to 0.480.41±0.20.40 to 0.41>0.05
  • * Unpaired t test.

  • χ2 test.

  • Mann–Whitney U test.

  • CNV, choroidal neovascularisation.